Laura von Schantz

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 5

Top Topics

Magnetic Resonance

Toll Like Receptor

Top Venues

Cancer immunology, immunotherapy : CII

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Barnabas Nyesiga, Mattias Levin, Anna Säll, Anna Rosén, Kim Jansson, Sara Fritzell, Karin Hägerbrand, Dietmar Weilguny, Laura von Schantz
RUBY® - a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties. mAbs 16 (1) (2024)
Barnabas Nyesiga, Mattias Levin, Anna Säll, Anna Rosén, Kim Jansson, Sara Fritzell, Karin Hägerbrand, Dietmar Weilguny, Laura von Schantz
RUBY® - a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties. mAbs 16 (1) (2024)
Barnabas Nyesiga, Mattias Levin, Anna Säll, Anna Rosén, Kim Jansson, Sara Fritzell, Karin Hägerbrand, Dietmar Weilguny, Laura von Schantz
RUBY® - a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties. mAbs 16 (1) (2024)
Karin Enell Smith, Sara Fritzell, Anneli Nilsson, Karin Barchan, Anna Rosén, Lena Schultz, Laura Varas, Anna Säll, Nadia Rose, Maria Håkansson, Laura von Schantz, Peter Ellmark
ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1. Cancer immunology, immunotherapy : CII (2023)
Michelle H Nelson, Sara Fritzell, Robert Miller, Doreen Werchau, Danielle Van Citters, Anneli Nilsson, Lynda Misher, Lill Ljung, Robert Bader, Adnan Deronic, Allison G Chunyk, Lena Schultz, Laura A Varas, Nadia Rose, Maria Håkansson, Jane Gross, Christina Furebring, Peter Pavlik, Anette Sundstedt, Niina Veitonmäki, Hilario J Ramos, Anna Säll, Anna Dahlman, David Bienvenue, Laura von Schantz, Catherine J McMahan, Maria Askmyr, Gabriela Hernandez-Hoyos, Peter Ellmark
The bispecific tumor antigen-conditional 4-1BB x 5T4 agonist, ALG.APV-527, mediates strong T cell activation and potent anti-tumor activity in preclinical studies. Molecular cancer therapeutics (2022)